Bretazenil (Ro16-6028) is an imidazopyrrolobenzodiazepine anxiolytic drug which is derived from the benzodiazepine family, and was invented in 1988. It is most closely related in structure to the benzodiazepine antagonist flumazenil, although its effects are somewhat different. It is classed as a high-potency benzodiazepine due to its high affinity binding to benzodiazepine binding sites where it acts as a partial agonist. Its profile as a partial agonist and preclinical trial data suggests that it may have a reduced adverse effect profile. In particular bretazenil has been proposed to cause a less strong development of tolerance and withdrawal syndrome. Bretazenil differs from traditional 1,4-benzodiazepines by being a partial agonist and because it binds to α1, α2, α3, α4, α5 and α6 subunit containing GABAA receptor benzodiazepine receptor complexes. 1,4-benzodiazepines bind only to α1, α2, α3 and α5 GABAA benzodiazepine receptor complexes.

CAS：84379-13-5
中文别名：
英文别名：Ro-16-6028;
分子式：C19H20BrN3O3
分子量：418.284
精确质量：417.069
Psa：64.43
Logp：3.8187

UNII：OSZ0E9DGOJ

密度：1.56g/cm3
沸点：594.3ºC at 760 mmHg
闪点：313.2ºC
折射率：1.685
储存条件：2-8ºC

安全说明：S22; S24/25